                         SEQUENCE LISTING

<110>  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
 
<120>  METHODS OF TREATMENT FOR CANCER, STEROL HOMEOSTASIS, AND 
       NEUROLOGICAL DISEASES

<130>  UTFB.P1155WO

<150>  US 62/462,435
<151>  2017-02-23

<160>  9     

<170>  PatentIn version 3.5

<210>  1
<211>  528
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic oligonucleotide

<400>  1
atgggggctc cggcaaccag gcgctgcgtg gagtggctgc tgggcctcta cttcctcagc       60

cacatcccca tcaccctgtt catggacctg caggcggtgc tgccgcgcga gctctaccca      120

gtcgagttta gaaacctgct gaagtggtat gctaaggagt tcaaagaccc actgctacag      180

gagcccccag cctggtttaa gtcctttctg ttttgcgagc ttgtgtttca gctgcctttc      240

tttcccattg caacgtatgc cttcctcaaa ggaagctgca agtggattcg aactcctgca      300

atcatctact ctgttcacac catgacaacc ttaattccga tactctccac atttctgttt      360

gaggatttct ccaaagccag tggtttcaag ggacaaagac ctgagacttt gcatgaacgg      420

ttaacccttg tgtctgtcta tgccccctac ttactcatcc cattcatact tttaattttc      480

atgttgcgga gcccctacta caagtatgaa gagaaaagaa aaaaaaaa                   528


<210>  2
<211>  176
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic polypeptide

<400>  2

Met Gly Ala Pro Ala Thr Arg Arg Cys Val Glu Trp Leu Leu Gly Leu 
1               5                   10                  15      


Tyr Phe Leu Ser His Ile Pro Ile Thr Leu Phe Met Asp Leu Gln Ala 
            20                  25                  30          


Val Leu Pro Arg Glu Leu Tyr Pro Val Glu Phe Arg Asn Leu Leu Lys 
        35                  40                  45              


Trp Tyr Ala Lys Glu Phe Lys Asp Pro Leu Leu Gln Glu Pro Pro Ala 
    50                  55                  60                  


Trp Phe Lys Ser Phe Leu Phe Cys Glu Leu Val Phe Gln Leu Pro Phe 
65                  70                  75                  80  


Phe Pro Ile Ala Thr Tyr Ala Phe Leu Lys Gly Ser Cys Lys Trp Ile 
                85                  90                  95      


Arg Thr Pro Ala Ile Ile Tyr Ser Val His Thr Met Thr Thr Leu Ile 
            100                 105                 110         


Pro Ile Leu Ser Thr Phe Leu Phe Glu Asp Phe Ser Lys Ala Ser Gly 
        115                 120                 125             


Phe Lys Gly Gln Arg Pro Glu Thr Leu His Glu Arg Leu Thr Leu Val 
    130                 135                 140                 


Ser Val Tyr Ala Pro Tyr Leu Leu Ile Pro Phe Ile Leu Leu Ile Phe 
145                 150                 155                 160 


Met Leu Arg Ser Pro Tyr Tyr Lys Tyr Glu Glu Lys Arg Lys Lys Lys 
                165                 170                 175     


<210>  3
<211>  19
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide

<400>  3

Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn 
1               5                   10                  15      


Pro Gly Pro 
            


<210>  4
<211>  25
<212>  RNA
<213>  Artificial sequence

<220>
<223>  Synthetic oligonucleotide

<400>  4
caaccuguug cggugguacu cuaag                                             25


<210>  5
<211>  25
<212>  RNA
<213>  Artificial sequence

<220>
<223>  Synthetic oligonucleotide

<400>  5
cuuagaguac caccgcaaca gguug                                             25


<210>  6
<211>  20
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic primer

<400>  6
tacttcgtct cgcacatccc                                                   20


<210>  7
<211>  20
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic primer

<400>  7
ttgctgaact cctgcgggta                                                   20


<210>  8
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic primer

<400>  8
cccgcgagta caaccttctt g                                                 21


<210>  9
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic primer

<400>  9
gtcatccatg gcgaactggt g                                                 21


